Afatinib, Osimertinib, Carboplatin and Pemetrexed — Competitive Intelligence Brief

Afatinib, Osimertinib, Carboplatin and Pemetrexed (Afatinib, Osimertinib, Carboplatin and Pemetrexed) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor, Platinum-based chemotherapy, Antifolate. Area: Oncology.

phase 2 Tyrosine kinase inhibitor, Platinum-based chemotherapy, Antifolate EGFR, DNA Oncology Small molecule

Target snapshot

Afatinib, Osimertinib, Carboplatin and Pemetrexed (Afatinib, Osimertinib, Carboplatin and Pemetrexed) — Amsterdam UMC, location VUmc. Afatinib and Osimertinib are irreversible tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), while Carboplatin is a platinum-based chemotherapy drug that works by crosslinking DNA, and Pemetrexed is an antifolate drug that inhibits thymidylate synthase.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Afatinib, Osimertinib, Carboplatin and Pemetrexed TARGET	Afatinib, Osimertinib, Carboplatin and Pemetrexed	Amsterdam UMC, location VUmc	phase 2	Tyrosine kinase inhibitor, Platinum-based chemotherapy, Antifolate	EGFR, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor, Platinum-based chemotherapy, Antifolate class)

1. Amsterdam UMC, location VUmc · 1 drug in this class